WO1999037770A1 - Phagocytosis genes and uses thereof - Google Patents
Phagocytosis genes and uses thereof Download PDFInfo
- Publication number
- WO1999037770A1 WO1999037770A1 PCT/US1999/001361 US9901361W WO9937770A1 WO 1999037770 A1 WO1999037770 A1 WO 1999037770A1 US 9901361 W US9901361 W US 9901361W WO 9937770 A1 WO9937770 A1 WO 9937770A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- protein
- amino acid
- acid sequence
- nucleic acid
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 236
- 206010057249 Phagocytosis Diseases 0.000 title claims abstract description 67
- 230000008782 phagocytosis Effects 0.000 title claims abstract description 67
- 101000871508 Homo sapiens PTB domain-containing engulfment adapter protein 1 Proteins 0.000 claims abstract description 304
- 102100033719 PTB domain-containing engulfment adapter protein 1 Human genes 0.000 claims abstract description 295
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 176
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 143
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 113
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 98
- 230000001640 apoptogenic effect Effects 0.000 claims abstract description 89
- 241000282414 Homo sapiens Species 0.000 claims abstract description 66
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 230000019491 signal transduction Effects 0.000 claims abstract description 44
- 239000003623 enhancer Substances 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 241000244206 Nematoda Species 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 272
- 150000001413 amino acids Chemical class 0.000 claims description 75
- 241001465754 Metazoa Species 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 73
- 101150091502 ced-6 gene Proteins 0.000 claims description 63
- 239000002773 nucleotide Substances 0.000 claims description 47
- 125000003729 nucleotide group Chemical group 0.000 claims description 47
- 230000009261 transgenic effect Effects 0.000 claims description 47
- 230000014509 gene expression Effects 0.000 claims description 45
- 230000007547 defect Effects 0.000 claims description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 28
- 108020004414 DNA Proteins 0.000 claims description 26
- 210000004962 mammalian cell Anatomy 0.000 claims description 26
- 108700008625 Reporter Genes Proteins 0.000 claims description 24
- 210000002149 gonad Anatomy 0.000 claims description 24
- 239000013598 vector Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 210000004292 cytoskeleton Anatomy 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 13
- 239000007850 fluorescent dye Substances 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 12
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 12
- 239000005090 green fluorescent protein Substances 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 11
- 230000004054 inflammatory process Effects 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 10
- 230000002500 effect on skin Effects 0.000 claims description 10
- 230000004770 neurodegeneration Effects 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 102000007469 Actins Human genes 0.000 claims description 9
- 108010085238 Actins Proteins 0.000 claims description 9
- 239000012082 adaptor molecule Substances 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 210000002919 epithelial cell Anatomy 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000004568 DNA-binding Effects 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 208000007056 sickle cell anemia Diseases 0.000 claims description 6
- 238000013518 transcription Methods 0.000 claims description 6
- 230000035897 transcription Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 101000917519 Homo sapiens rRNA 2'-O-methyltransferase fibrillarin Proteins 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 210000002510 keratinocyte Anatomy 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 102100029526 rRNA 2'-O-methyltransferase fibrillarin Human genes 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000000799 fluorescence microscopy Methods 0.000 claims description 4
- 238000000386 microscopy Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 2
- -1 linker compound Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 86
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 claims 4
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 3
- 230000000242 pagocytic effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 43
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000031295 Animal disease Diseases 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 75
- 210000004602 germ cell Anatomy 0.000 description 48
- 239000002299 complementary DNA Substances 0.000 description 45
- 230000035939 shock Effects 0.000 description 43
- 230000002018 overexpression Effects 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 29
- 101100220237 Caenorhabditis elegans ced-6 gene Proteins 0.000 description 27
- 210000002107 sheath cell Anatomy 0.000 description 24
- 101150046002 ced-1 gene Proteins 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 230000000392 somatic effect Effects 0.000 description 20
- 210000002257 embryonic structure Anatomy 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 230000030833 cell death Effects 0.000 description 18
- 230000002068 genetic effect Effects 0.000 description 17
- 230000002085 persistent effect Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 235000013930 proline Nutrition 0.000 description 16
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 15
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108700028369 Alleles Proteins 0.000 description 14
- 101100220239 Caenorhabditis elegans ced-7 gene Proteins 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 11
- 108091060211 Expressed sequence tag Proteins 0.000 description 10
- 238000003782 apoptosis assay Methods 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 230000005522 programmed cell death Effects 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000013020 embryo development Effects 0.000 description 8
- 101150066555 lacZ gene Proteins 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108020005544 Antisense RNA Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 102000050197 human GULP1 Human genes 0.000 description 7
- 238000000520 microinjection Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008521 reorganization Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 108050008861 SH3 domains Proteins 0.000 description 5
- 102000000395 SH3 domains Human genes 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000005056 cell body Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 101150039113 unc-36 gene Proteins 0.000 description 5
- 101100139831 Caenorhabditis elegans ced-10 gene Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 101150117572 ced-2 gene Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 241001156002 Anthonomus pomorum Species 0.000 description 3
- 241000244201 Caenorhabditis briggsae Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- 102100031598 Dedicator of cytokinesis protein 1 Human genes 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002308 embryonic cell Anatomy 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 101100008648 Caenorhabditis elegans daf-4 gene Proteins 0.000 description 2
- 101100459896 Caenorhabditis elegans ncl-1 gene Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101710113370 Dedicator of cytokinesis protein 1 Proteins 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 description 2
- 101000866235 Homo sapiens Dedicator of cytokinesis protein 1 Proteins 0.000 description 2
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 description 2
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 108091036407 Polyadenylation Proteins 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000001152 differential interference contrast microscopy Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 238000012252 genetic analysis Methods 0.000 description 2
- 210000002980 germ line cell Anatomy 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000010196 hermaphroditism Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 108091005981 phosphorylated proteins Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102100036439 Amyloid beta precursor protein binding family B member 1 Human genes 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 241001485018 Baboon endogenous virus Species 0.000 description 1
- 241000714266 Bovine leukemia virus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100071585 Caenorhabditis elegans hsp-16.2 gene Proteins 0.000 description 1
- 101100353517 Caenorhabditis elegans pas-2 gene Proteins 0.000 description 1
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100028572 Disabled homolog 2 Human genes 0.000 description 1
- 101710197163 Disabled homolog 2 Proteins 0.000 description 1
- 108700029762 Drosophila crq Proteins 0.000 description 1
- 108700042732 Drosophila dab Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000663831 Homo sapiens SH3 and PX domain-containing protein 2A Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 101150103927 Numb gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- UACPLQANRQVKHE-UHFFFAOYSA-N [amino-[(4-hydroxyphenyl)methyl]phosphanyl]formic acid Chemical compound OC(=O)P(N)CC1=CC=C(O)C=C1 UACPLQANRQVKHE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002922 epistatic effect Effects 0.000 description 1
- 229940064258 estrace Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000050223 human DOCK1 Human genes 0.000 description 1
- 102000057479 human SH3PXD2A Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 101150079143 mec-4 gene Proteins 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000034004 oogenesis Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000005894 phagocytic removal Effects 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091005451 scavenger receptor class A Proteins 0.000 description 1
- 102000035013 scavenger receptor class A Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000002262 tip cell Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Definitions
- Phagocytosis or engulfment is a specialized form of endocytosis through which eukaryotes take up very large particles, or even whole cells. It is a fundamental biological process conserved from single-cell organisms, such as amoebae to mammals (Metchnikoff, E. 1891), Lectures on the comparative pathology of inflammation; delivered at the Pasteur Institute, 1891, 1968 Edition (New York: Dover Publication)). Initially used for the dual purpose of feeding and defence, phagocytosis evolved, following the emergence of mesoderm, into a mechanism used to protect the host against invading organisms and to clear up foreign particles and cell debris (Metchnikoff, 1891).
- phagocytosis has been extended due to its role in eliminating cells undergoing programmed cell death (apoptosis). Since apoptosis has been implicated in a number of human diseases elucidation of the regulation of this phagocytosis is -2-
- CED-6 acts within engulfing cells, and functions to promote the removal of both early and persistent cell corpses. Overexpression of CED-6 can partially suppress the engulfment defect of both CED-1 and CED-7, suggesting that CED-6 functions downstream of these two genes.
- CED-6 acts as an adaptor molecule in a signal transduction pathway that mediates the engulfment of apoptotic cells in C. elegans.
- the present inventors have also identified isolated and characterized human CED- 6 homologue including a splice variant thereof, which it is shown is involved in a similar process in mammalian cells.
- the invention provides, in isolated form, a protein which is the CED-6 protein of C. elegans or a protein which has equivalent function thereto and human homologues of the protein, hereinafter referred to as hlCED-6, h2CED-6, and h3CED-6.
- the invention further provides a functional fragment of CED-6, hlCED-6, h2CED-6 and h3CED-6, for example, a fragment corresponding to the phosphotyrosine binding domain and/or the proline/serine rich region.
- the invention further provides an isolated nucleic acid encoding CED-6 and human homologues of CED-6, as well as nucleic acid encoding functional fragments of CED-6, hlCED-6, h2-CED-6 and h3-CED-6 as described above. -3-
- the invention further provides nucleic acid which is antisense to any of the nucleic acids described above or which is capable of hybridizing to any of the nucleic acids described above under conditions of low, medium or high stringency or portions or fragments thereof.
- the invention further provides expression vectors comprising nucleic acid encoding CED-6, hlCED-6, h2CED-6, h3CED-6 or encoding functional fragments of said proteins as above.
- the invention further provides mammalian cell-lines transfected with one or more nucleic acids encoding CED-6, hlCED-6, h2CED-6, and or h3CED-6.
- the invention further provides assay methods using the proteins, nucleic acids and transfected cells described above to identify compounds which enhance or inhibit the signal transduction pathway in which CED-6, hlCED-6, h2CED-6, and/or h3CED-6 participate.
- the invention further provides assay methods using the transfected cells described above to identify compounds which enhance or inhibit the expression of the CED-6, hlCED-6, h2CED-6 or h3CED-6 genes.
- the invention further provides antibodies which react with an epitope of CED-6, hlCED-6, h2CED-6, and/or h3CED-6.
- the invention further provides a method of treating diseases the etiology of which may be attributed to failure of engulfment of apoptotic or other diseased cells such as inflammation autoimmune disease or cancer by administering to a patient one or more of the aforesaid proteins or nucleic acids or compounds which are enhancers of CED-6, hlCED-6, h2CED-6 or h3CED-6.
- the invention further provides a method of treating diseases which would benefit from a reduction in the engulfment of apoptotic cells, such as, neurodegenerative diseases, stroke, or sickle-cell anaemia, by administering one or more of the aforesaid proteins, nucleic acids or compounds which are inhibitors of CED-6, hlCED-6, h2CED-6, or h3CED-6.
- the invention further provides a method of diagnosis of a human or animal disease using a nucleic acid encoding CED-6, hlCED-6, h2CED-6 or h3CED-6 or -4-
- the invention further provides a method of identifying proteins which interact with CED-6, hlCED-6, h2CED-6 or h3CED-6 in the signal transduction pathway in which those proteins participate.
- the invention further provides a fusion protein in which CED-6, hlCED-6, h2CED-6 or h3CED06 or a functional fragment thereof such as the phosphotyrosine binding domain or serine proline rich region, is fused to another protein such as an epitope tag or product of a reporter gene .
- the invention further provides a method of determining whether a compound is an enhancer or inhibitor of the signal transduction pathway in which CED-6 participates by observing the effect of the compound on C. elegans worms having altered CED-6 expression.
- Figure 1A - IE are schematic representation of the CED-6 Locus.
- FIG. 1 A Genetic map of CED-6. CED-6 and some genes close to and also used to map CED-6 are shown.
- Figure IB Cosmid rescue. Transgenic animals carrying cosmids or subcloned DNA fragments (see C, D) were examined for cell corpses on three fold embryos. Those who gave embryos with partial or no cell corpses were counted as rescuing transgenic lines. Four out of tested thirteen cosmids are shown. Rescuing fragments are bold. Number represents # rescuing lines/ # lines tested.
- Figure 1C Subcloning of F56D2 cosmid and rescue. Restriction map of the CED-6 region is shown on the top. In the middle, several restriction fragments were tested for their ability to rescue the engulfment defect caused by CED-6(nl813).
- Figure ID Subcloning of 10 kb Xlio I fragment and rescue.
- RT-PCR products of 5' end of F56D2.7 contain both SL1 and SL2.
- Figures 2A and B shows that F56D2.7 Encodes CED-6.
- Figure 2A shows the full-length cDNA (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) of C. elegans CED-6.
- Double underline shows the nucleic acid (SEQ ID NO: 3) and amino acid sequence (SEQ ID NO: 4) of phosphotyrosine binding (PTB) domain; single underline indicates the nucleic acid (SEQ ID NO: 6) and the amino acid (SEQ ID NO: 7) sequence of the proline/serine rich region.
- Dashed underline indicates charged region.
- Star identifies the prolines in the PxxP signature sequence, empty triangles the charged residues within the dashed region. Shaded box indicates polyadenylation signal.
- Both SL1 and SL2 could be added to transplicing acceptor site.
- the single base pair deletion identified in CED-6(nl813) is shown.
- Figure 2B Southern blot which revealed a RFLP on 4.1 kb fragment from CED-6 (n2095).
- Xho I probe identifies an allele-specific RFLP in CED-6(n2095) that affect a 4.1 kb Hind III fragment containing F56D2.7.
- On the right bottom the genomic fragments digested by Hind III on the Xho I fragment region is shown.
- Figure 3A-C show that CED-6 Contains a Phosphatyrosine Binding Domain.
- Figure 3 A shows that alignment of CED-6 PTB (SEQ ID NO: 4) with other PTB domain. The PTB domain alignment was based on the NMR structure of She protein. Black boxes indicate identical amino acids showed by >50% of sequences. Grey boxes indicate similar amino acid showed by >50% of sequences. For this purpose, the following sets of amino acids are considered similar: G, A, C, S, T; E, D, Q, N; R, K, H; V, M, L, I; F, Y, W. ⁇ indicate the a -6-
- FIG. 3B shows the comparison of CED-6 to other PTB domain containing proteins. Proline rich regions and charged regions next to PTB domains and other regions. PTB domains were compared in the percentage of identity.
- Figure 3C shows the evolution tree of the PTB domains. The alignment from (A) was displayed using Seqlab package in GCG program, and the evolution tree was grown graphically.
- Figure 4 shows results of the Genetic Mosaic Analysis for CED-6 (table at bottom) and Cell lineage of C. elegans (top). The descendence of both germline and somatic sheath cells are illustrated. Body wall muscles cells which were used to determine the loss of the duplication were also illustrated. The solid square indicates the duplication loss in germ cells, and the solid square indicates the duplication loss in the somatic sheath cells. The black arrow indicates the somatic sheath cell with the enlarged nucleoli in the distal arm of the anterior gonad. The white arrow indicates the cell corpses accumulated in the proximal arm of anterior gonad.
- Figure 5A-D provide results that showed that heat-shock overexpression of CED-6 cDNA rescued the engulfment defect in both soma and germline.
- Figure 5A shows the cell death during the embryonic development. Shaded box is a histogragh indicating the number of dying cells every 50 minutes during the embryonic development. The arrows indicates the timing of heat shock and the timing to observe the engulfment phenotype.
- Figure 5B shows the overexpression of CED-6 cDNA promotes the engulfment at both the early and the late stage of cell death. Transgenic animals carrying the transgene, CED-6 cDNA driven by heat shock promoter were treated with heat before the cell death occurred at the indicated time. Cell Corpses in the head of young LI larvae were examined.
- Figure 5C shows the overexpression of CED-6 cDNA rescue the engulfment defect in germline.
- the arrow indicates the timing for a heat shock when transgenic animals were at the development stage of the 24 hours after the L4 molt. Cell corpses were examined at the several time points between the time of heat shock and the 60 hours after the heat shock.
- Figure 5D shows the overexpression of CED-6 cDNA promotes the engulfment many hours after the formation of the cell corpses in germline.
- Adult transgenic animals were treated with heat as indicated. Cell corpses were examined in one gonad arm 12 hours after the heat shock. Control experiments including N2, and CED-6(nl813) are indicated in (C).
- FIG. 6 presents results that show overexpression of CED-6 partially suppresses the engulfment defect of both CED-1 and CEDX during embryonic development
- CED-6 was overexpressed at the genetic background of three alleles of both CED-1 and CEDX.
- the timing for the heat shock and the timing for the examination of cell corpses are illustrated in figure 5 A. Animals with each genetic background were treated with heat before the cell death occurred or without the heat treatment. Cell corpses were examined in head of young LI larvae. LacZ was also expressed in the each genetic background. Each mutant was also treated with heat shock to examine the effect of heat on the expression of cell corpses.
- Figure 7 is a model of the epistatic pathway for the engulfment genes overexpression of CED-6 did not have an obvious effect on the cell corpses expression on CEDX, 5 and 10 but on CED-1 and CEDX.
- CED-6 might act downstream of both CED-1 and CEDX.
- CEDX, 5 and 10 either act in the different pathway or act downstream of CED-6.
- Figure 8 is a flow chart illustrating a Xho I fragment from F56 cosmid rescues the CED-6 engulfment defect.
- Figure 9A-B are schematics that illustrate that the C05D2.7 construct is CED-6.
- Figure 9A shows the restriction Map of Xho I fragment and rescue.
- Figure 9B shows the transcripts. -8-
- Figure 10 is a bar graph illustrating that the over-expression of CED-6 rescues the engulfment defect of the CED-6 mutant.
- Figure 11 contains graphs illustrating that the over-expression of CED-6 rescues the engulfment defect of CED-6 mutant during embryonic development.
- Figure 12 is a bar graph illustrating that CED-6 may also promote the engulfment of persisting corpses.
- Figure 13 shows that CED-6 promotes the engulfment of persistent cell corpses and probably acts within engulfing cells.
- FIG. 14 is a schematic that shows that CED-6 may be an adaptor protein acting in signal transduction pathway.
- Figure 15 shows graphs which indicate that over-expression of CED-6 rescues the engulfment defect in the adult gonad, and CED-6 might act in somatic sheath cells.
- Figure 16 illustrates that over-expression of CED-6 partially suppresses the engulfment defect of CED- 1 mutants .
- Figure 17 shows that the over-expression of CED-6 cDNA suppresses the engulfment defect of CED-7 mutants.
- Figure 18 shows consensus DNA sequence (SEQ ID NO: 7) of hlCED-6 (2416bp) with start and stop codon in bold and alternatively spliced sequence underlined.
- Figure 19 shows DNA sequence (SEQ ID NO: 13) of h2CED-6 (alternative splice) with start and stop codons in bold.
- Figure 20 shows the amino acid sequence (SEQ ID NO: 8) of hlCED-6 with alternatively spliced region underlined.
- Figure 21 shows the amino acid sequence (SEQ ID NO: 14) of h2CED-6
- Figure 22 shows hlCED-6 cDNA (SEQ ID NO: 7) and hlCED-6 (SEQ ID NO: 8) amino acid sequence with PTB domain nucleic (SEQ ID NO: 9) and amino acid (SEQ ID NO: 10) sequences, charged region, and proline/serine rich nucleic acid (SEQ ID NO: 1 1) and amino acid (SEQ ID NO: 12) sequences indicated. -9-
- Figure 23 shows an alignment of CED-6 and hlCED-6.
- Figure 24 shows an alignment of regions of 47.5% and 31.6% identity, respectively.
- FIG. 25A Human Multiple Tissue Northern Blot (MTN)
- Figure 25B shows a Human Multiple Tissue Northern (MTN) Blot II
- Figure 25C shows a Human Cancer Cell Line Multiple Tissue Northern (MTNTM) Blot. The expression pattern of hlCED-6 in normal human tissues and cancer cell lines by Northern blotting is shown.
- Figure 26 is a map of plasmid pGA3015 in which a CED-6 fragment is cloned as a C-terminal fusion to GFP.
- Figure 27 is a map of plasmid pGA3064 with CED-6 cloned as a C- terminal fusion of GFP.
- Figure 28A-28F is a DNA alignment (Genework) of sequenced hbc3123 EST clone, the PCR fragment I isolated from a cDNA library, and three EST sequences identified using the PCR fragment.
- hbc3123 EST clone was sequenced and analyzed. The three EST clones were identified through searching the Genbank using the isolated PCR fragment.
- Figure 29 shows the amino acid sequence (SEQ ID NO: 16) of the human h3 CED-6, as compared to hlCED-6 (SEQ ID NO: 8).
- Figures 30A-B show the nucleic acid sequence (SEQ ID NO: 15) that encodes human h3 CED-6, as compared to hlCED-6 (SEQ ID NO: 7).
- Figures 31A-B show that overexpression of h3CED-6 rescue an engulfment defect.
- Figures 31 A shows overexpression ⁇ hCED-6 rescued the engulfment defect of CED-6(nl813) embryos. Embryos laid by transgenic mothers were heat- shocked before the wave of embryonic cell death, and scored for the numbers of persistent cell corpses in head of LI larvae. Each dot represents one animal.
- Figure 3 IB shows overexpression of hCED-6 rescued the germ cell engulfment defect of CED-6(nl813) animals. Transgenic animals were heat-shocked 36 hours after L4/adult molt, and germ cell corpses were scored 12 hours after heat shock. The number of animals scored is indicated on the top of each bar. -10-
- Figure 32A-J shows the nucleic acid sequence comparison among ESTs, CED-6, hCED-6, and a consensus construction of 2416 bp consensus sequence was done by using sequence information obtained from EST RACE & colony hybridization. Seq was compiled by using aal 599394 as template and primers as indicated in multiple alignment. Rcc stands for the reverse complement. Both CED-6 and hCED-6 are indicated above the multiple alignment pGAlOl was picked up by colony hybridization.
- SEQ. ID NO. 1 Nucleic acid sequence of C. elegans CED-6. (e.g.. Figure 2A)
- SEQ. ED NO. 3 Nucleotide sequence encoding PTB domain of C. elegans CED-6 (e.g., Figure 2A)
- SEQ. ID NO. 4 Ammo acid sequence of PTB domain of C. elegans CED-6 (e.g., Figure 2A)
- SEQ. ID NO. 6 Ammo acid sequence of prohne/serum rich region of C. elegans CED-6 (e.g., Figure 2A)
- SEQ. ID NO. 7 Nucleotide sequence that encodes hlCED-6 (e.g., Figure 22, Figure 18)
- SEQ. ID NO. 8 Amino acid sequence of hlCED-6 (e.g.. Figure 20 and Figure 22)
- SEQ. ID NO. 9 Nucleotide sequence encoding PTB domain of hlCED-6 (e.g., Figure 22)
- SEQ. EO NO. 11 Nucleic acid sequence that encodes the prohne/se ⁇ ne rich region of hlCED-6 (e.g., Figure 22)
- SEQ. ID NO. 13 Nucleotide sequence that encodes h2CED-6 (e.g., Figure 1A)
- SEQ. ID NO. 16 Ammo acid sequence of h3CED-6 (e.s. Fieure 29) -12-
- Engulfment is also a swift and efficient process in the nematode Caenorhabditis elegans : dying cells are engulfed and completely removed by their neighboring cells within an hour (Sulston and Horvitz, (1977); Dev. Biol 56 pp 110-156; Robertson and Thomson, 1982). The engulfment is not necessarily by professional phagocytes. Rapid engulfment of apoptotic cells is important, as it prevents dying cells from releasing potentially harmful contents during their lysis, which could damage surrounding tissue and result in an inflammatory response (Duvall et al., (1985) Immunology 56 pp 351-358; Savill et al., (1989) J. Clin. Invest. 83 pp 865-875; Grigg et al, (1991) Lancet 358 pp 720-722; Savill et al., (1993) Immunol. Today 14, pp 131-136).
- C. elegans The nematode C. elegans has been used extensively for the study of programmed cell death (reviewed by Hengartner, (1997) Cell Death in C. elegans II, Plain View, Cold Spring Harbour Laboratory Press, pp 383-415). Genetic studies have identified over a dozen genes that function in the regulation and execution of apoptosis in C. elegans. Six genes - CED-1, CED-2, CED-5, CED-6, CED-7, and CED-10 - function in the engulfment of all dying cells (Hedgecock et al., 1983; Ellis et al., 1991; Horvitz et al., (1994) Cold Spring Harbour Symp. Quant Biol (1994) 59: pp 377-385). In animals mutant for any one of these genes, many apoptotic cells fail to be engulfed and persist for many hours as highly refractile disks that can be readily identified under differential interference contrast -13-
- apoptotic receptors have been identified over the past few years; these include the ATP -binding cassette transporter ABCl (Luciani and Chimini, (1996), EMBO J. f5 pp 226-235) adhesion molecules such as the vitronectin receptor (Savill et al (1990), Nature 343 pp 170-173) and CD36 (Asch et al. (1987) J. Clin. Invest. 79 pp 1054-1061; Savill et al (1992) J. Clin. Invest. 90 pp 1513-1522; Ren et al (1995) J. Exp. Med.
- apoptosis has been implicated in the etiology, or associated with the pathology, of a wide range of diseases, including cancer, autoimmune diseases, various neurodegenerative diseases such as Amyotrophic Lateral -14-
- Persistent apoptotic bodies can often be observed following chemotherapeutic intervention (which leads to extensive apoptosis) and are particularly abundant in solid tumors, in which clearance of cell corpses might be delayed.
- professional phagocytes carry specific surface receptors, such as the Fc (Ravetch, (1994) Cell 78 553-560; Greenberg et al., (1993) J. Exp. Med. 177 pp 529-534) and C3 (Bianco et al., (1975) J. Exp. Med. Hi pp 1278-1290; Greenberg, (1995) Trends in Cell Biol.
- the invention relates to an isolated protein which is an adaptor molecule in a signal transduction pathway which regulates phagocytosis of apoptotic cells.
- the invention pertains to an isolated protein from the nematode worm C. elegans which is an adaptor molecule acting in a signal transduction pathway which promotes phagocytosis of apoptotic cells, which protein comprises the amino acid sequence shown in Figure 2A (SEQ ID NO: SEQ ID NO: amino acid sequence shown in Figure 2A
- Figure 2 A is that of the C. elegans CED-6 protein with its encoding DNA also shown.
- the invention comprises a nucleic acid comprising a sequence of nucleotides which encodes the amino acid sequence of Figure 2 A, (SEQ ID No: 2) for example, a sequence of nucleotides from about nucleotide position 22 to about nucleotide position 1500 of Figure 2 A or the entire sequence of nucleotides shown in Figure 2 A.
- an isolated protein which is a fragment or portion of a protein having the amino acid sequence of Figure 2 A or of a protein having an amino acid sequence which differs from that shown in Figure 2A only in conservative amino acid changes.
- the portion may comprise an amino acid sequence corresponding to the phosphotyrosine binding domain (SEQ ID No: 4) (about amino acid 46 to about amino acid 193 in Figure 2 A) or an amino acid sequence corresponding to the proline/serine rich region (SEQ ID No: 6) (about amino acid 242 to about amino acid 339 in Figure 2A).
- Nucleic acids (SEQ ID Nos: 3 and 5 respectively) encoding the PTB domain or the proline/serine rich region of the C. elegans CED-6 protein are encompassed by the claimed invention. -16-
- an isolated nucleic acid capable of hybridizing to the sequence of nucleotides of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15 under conditions of low, medium or high stringency. It is to be understood that low stringency means approximately: 0.2 to 2xSSC; 0.1% SDS; 25° to 50°C.
- a fusion protein which comprises as part of the fusion a protein having an amino sequence of SEQ ID No: 2, 4, 6, 8, 10, 12, 14, or 16 or an amino acid sequence which differs from the amino acid sequence shown in SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, or 16 only in conservative amino acid changes.
- the protein may be fused to, for example, an epitope tag or the expression product of a reporter gene.
- the invention provides expression vectors comprising any of the nucleic acid sequences of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15.
- the vectors incorporate a reporter gene such as green fluorescent protein which is positioned relative to the nucleic acid of the invention such that expression of the nucleic acid results in expression of the reporter gene.
- a reporter gene such as green fluorescent protein which is positioned relative to the nucleic acid of the invention such that expression of the nucleic acid results in expression of the reporter gene.
- a fusion of CED-6 and the reporter gene is expressed.
- nucleic acid may include genomic DNA, RNA and cDNA.
- Positional cloning methods were used to clone the C. elegans CED-6 gene and determine the nucleotide sequence. In addition they have functionally characterized the protein. By searching publicly available protein sequence databases, it has been determined that the CED-6 protein has in the N-terminal half a putative phosphotyrosine binding domain and in the C-terminal half a proline/serine rich region which is a potential SH3 binding domain.
- upstream transcript C05D2.6A is trans-spliced to the more common SL1 splice leader ( Figure IE).
- CED-6 Transcripts To confirm the predicted intron/exon structure for CED-6, the present inventor screened a mixed-stage cDNA library and identified 10 clones corresponding the CED-6 gene. Several of these contained splice leader SL2 sequences at the 5' end, suggesting that CED-6 might also be a downstream gene in an operon. RT-PCR was performed on mixed-stage RNA using both SL1 and SL2 trans-splicing leaders as primers for the PCR step. Interestingly, sequence analysis of the PCR-amplified fragments revealed that both SL1 and SL2 trans- splicing leaders can be found at the 5' end of CED-6 transcripts (Figure 2B). The upstream gene in the CED-6 operon is the predicted gene F56D2.1. The presence -19-
- CED-6 Protein Contains a Phosphotyrosine Binding (PTB) Domain and a Proline/Serine Rich Region
- the full-length CED-6 cDNA is predicted to code for a 492 amino acid protein (Figure 2B).
- a search of public sequence database with the predicted CED-6 sequence indicated that the N-terminal half of CED-6 contains a putative phospho-tyrosine binding (PTB) domain.
- PTB domains can promote binding to phosphorylated tyrosine residues located within an appropriate primary sequence context.
- the PTB domain is similar in function, but distinct in structure from the SH2 domain.
- the present inventors have aligned the CED-6 PTB domain with the PTB domains found in a number of other proteins (Figure 3A). Secondary structure prediction programs suggest that most of these structural elements also exist in the CED-6 PTB domain.
- CED-6 PTB domain In addition to its similarity to known proteins, the CED-6 PTB domain also showed significant sequence similarity to the predicted translation products of a number of expressed sequence tags (ESTs; Figure 3 A, B). In fact, the degree of similarity between CED-6 and a number of these ESTs was much higher than between CED-6 and any previously characterized protein ( Figure 3A, 3B). Furthermore, in several cases, the sequence similarity between CED-6 and ESTs extended beyond the PTB domain ( Figure 3B). CED-6 also contains a proline/serine rich region at its C-terminal half, with 42% serine over a 24 amino acids stretch and clusters of proline-rich regions ( Figure 2B, Figure 3B).
- proline-rich regions were characterized by several sequence signatures of PxxP ( Figure 2A), which has been shown to promote interaction with SH3 domains (Ren et al, (1993); Yu et al (1994) Cell 76 pp 933-945,; Grabs et al (1997) J. Biol, Chem. 272 pp 13419-13425). Between the PTB and proline-rich regions is a short -20-
- a genetic mosaic analysis was performed to determine if CED-6 acts within engulfing cells or dying cells. For convenience, a pair of cells on adult gonad, germ cells and somatic sheath cells ( Figure 4A) were used. During oogenesis large number of oocytes undergo programmed cell death, and normally these dying cells are engulfed by somatic sheath cells (Hengartner,1997). In this analysis a mosaic pattern of genetic background for CED-6 and wild type between germ cells and somatic sheath cells was generated.
- Ncl-1 mutant was used for the identification of the mosaic pattern in the single-cell resolution since in the Ncl-1 mutant somatic cells of animals exhibit abnormal enlarged nucleoli, which can be easily identified under Normaski optics (Herman, 1984; Genetics 108 pp 165-189; -21-
- mice To identify the animals with CED-6 mutant germ cells and wild-type somatic sheath cells, animals must be found with the duplication loss from any of P2, P3 and P4 lineages but not from EMS, MS or any lineages below the MS which would lead to the loss of the duplication in somatic sheath cells (Figure 4). These animals can be obtained by looking through many animals of the constructed strain for the animals laying only Dpy Unc progenies The animals with the loss of the duplication in PI lineage also lay only the Dpy Unc progenies, however these animals are not mosaic animals for the present purpose since the loss of the duplication in PI lineage results in the CED-6 mutant background in both germ cells and somatic sheath cells.
- F56D2.7 cDNA indeed corresponds to CED-6
- the invention includes methods to detect quickly if CED-6 acts within engulfing cells. This method is based on dying cells' failing to express proteins so as to generate a mosaic pattern of protein expression. However, this idea can be -24-
- CED-6 was over-espressed at the genetic background of CED-1, 7, 2, 5, and 10.
- the extra-chromosomal arrays carrying CEDX cDNA driven by heat shock promoters were transferred from CED-6(nl813) background to wild-type N2 background, and subsequently to CED-1. 7, 2, 5, and 10 mutant background.
- CED-6 was then over-exposed by following the method used for the rescue of CED-6 engulfment defect by the over-expression of CED- ⁇ cDNA as described in Figure 5 A. It was found that over-expression of CED-6 could partially suppress the engulfment defect for CED-7(nl997).
- CED-6 might rely on the 1 kb upstream region of CED-6 gene, a intergenic region of the operon.
- the Intergenic region of a operon sometimes could be used as a promoter for the expression of the downstream gene (Blementhal and Steward, (1997 C. elegans II) (Cold Spring Harbor; Cold Spring Harbor Laboratory Press pp 117-145)
- CED-6 is an Adaptor Molecule Acting in the Signal Transduction Pathway of the Engulfment
- Protein phosphorylation is a well-defined "switch" mechanism for cells to deliver signals from one protein to another, and it is essential to transduce extracellular signals inside cells.
- PTB domain is another domain besides the SH2 domain to be able to interact with a phosphorylated tyrosine residue (Kavanaugh and Williams, (1994) Science 266; Blaikie et al, (1994) J.Biol.Chem 269 32031- 32034).
- proteins containing PTB domains have been found to act as adaptor molecules in the signal transduction pathway.
- CED-6 contained stretches of prohne rich regions containing the PxxP signature, suggesting its potential to interact with the SH3 domam.
- CED-6 is an adaptor molecule that directly or indirectly transduces the signal from receptors to effectors or cytoskeleton molecules to initiate the engulfment process.
- the PTB domam has been shown to interact specifically with a NPXY(p) motif (Kavanaugh and Williams, 1994, Zhou et al, (1995) Nature 378 pp 584-592; Geer and Pawson, 1995).
- Many receptors such as EGF receptor, TrkA, insulin receptor, IGF-1 receptor contain this motif at the carboxyl terminal (Geer and Pawson, 1995). Signals from these receptors have been shown to be transduced through the interaction of a phosphotyrosine residue of this motif with PTB domains of adaptor molecules, such as She and msulm receptor substrate 1
- CEDX has been suggested to act in the same genetic pathway with CED-6 (Ellis et al, 1991). The inventors have shown that CEDX might act upstream of CED-6 ( Figure 7). CEDX encodes a ABC transporter, and its mammalian homologue, ABC1 was found to be required for the macrophage to engulf dying cells (Luciani and Chimini, 1996), suggesting that CEDX might act withm engulfing cells. It is possible for CED-6 to physically interact with CED-7 through a PTB domain with NPXY(p) motif of CED-7 to regulate the signal transduction of engulfment process
- CED-6 also contains a prolme/se ⁇ ne rich region with several sequence signature PxxP, which might mediate its interaction with the SH3 domain.
- the SH3 domain has been suggested to mediate protem-protem interactions between signaling molecules downstream of membrane-bound receptors (Koch et al, (1991) Science 252 pp 252-673; Pawson and Schlessinger, (1993) Current Biology 3 pp 434-442.
- a SH3 domam containing protein is likely to interact with CED-6 and to regulate the signal transduction pathway of engulfment.
- Several proteins might directly or indirectly interact with CED-6 protein CED-1 might act upstream of -28-
- the relationship between CED-1 and CED-6 will depend on the cloning of the gene.
- a protein with a phosphorylated tyrosine residue should exist to interact with the PTB domain of C ⁇ D-6.
- This phosphorylated protein is either a tyrosine kinase or a substrate of a tyrosine kinase, and a tyrosine phosphatase should also be involved in the signal transduction pathway of engulfment to down-regulate the activity of the phosphorylated proteins.
- CED-6 Over-expression of CED-6 promotes the engulfment of dying cells at a very early stage of the cell death, and cell corpses formed hours after the cell death.
- Cell corpses have been shown to have a typical morphology of apoptotic -29-
- CEDX is required for the engulfment.
- a few cell corpses in the gonad were not removed upon heat shock for some animals later after the heat shock. These corpses tend to be located in between oocytes and closed to the spermatheca. The failure of the engulfment of these cell corpses might be due to their lack of contact with the sheath cells.
- C. elegans CED-6 DNA was inserted into commercially available vectors, including vectors having the reporter gene, green fluorescent protein (GFP), are set out in table 1 below;
- GFP green fluorescent protein
- Tek chambered coverglass (Nalge Nunc International) and transfected using lipofectAMINE (GibcoBRL). After 18 hours, the chambered coverglasses where placed on a inverted microscope, and GFP fluorescence could be visualized.
- transfected MCF7 cells as above are useful for conducting assays to identify compounds which inhibit and enhance CED-6 or CED-6 as will be discussed hereafter.
- an isolated protein which is an adaptor molecule in a signal transduction pathway which regulates phagocytosis of apoptotic cells.
- an isolated protein which is a human homologue of C. elegans CED-6 which comprises an amino acid sequence as shown in Figure 20 or Figure 22 (SEQ ID No: 8) or an amino acid sequence which differs from that shown in Figure 20 only in conservative amino acid changes (hlCED-6).
- nucleic acid DNA RNA, cDNA or genomic DNA; SEQ ID NO: 7, 13, 15
- hlCED-6 h2CED-6 or h3CED-6 (SEQ ID Nos: 8, 14, 16) or a functional equivalent thereof.
- the invention encompasses a nucleic acid comprising the sequence of nucleotides from about nucleotide position 430 to about nucleotide position 1344 shown in Figure 18, Figure 19, or Figure 22 or the entire sequence of nucleotides shown in these figures.
- the invention includes the open reading frame of the nucleic acid sequence that encodes c. elegans CED-6, CED-6, h2CED-6 or h3CED-6.
- the invention also provides a protein which is a fragment of the protein with the amino acid sequence shown in Figure 20, Figure 22 or Figure 29 (SEQ ID No: 8, -32-
- the fragment may comprise a sequence of amino acids corresponding to the phosphotyrosine binding domain of SEQ ID NOs: 8, 14, 16.
- the PTB domain of SEQ ID Nos: 8 or 16 is from amino acids Nos. 15-157.
- the invention also pertains to the nucleic acid and amino acid sequences of the proline/serine rich domains of hlCED-6 and/or h3CED-6 (e.g., amino acid Nos.: 201-276 in Figures 20, 22, or 29).
- the highly charged region of SEQ ID NOs.: 8 or 16 is encompassed by the invention (e.g., amino acid Nos. 161-195 of Figures 20, 22 and 29).
- the invention includes the nucleic acid sequences that encode these fragments.
- a splice variant of h3CED-6 (referred to herein as h2CED-6) which variant comprises an amino acid sequence as shown in Figure 21 (SEQ ID No: 14) or an amino acid sequence which differs from that shown in Figure 21 only in conservative amino acid changes.
- a nucleic acid (DNA, RNA, cDNA or genomic DNA) encoding h2CED-6 (SEQ ID No: 13) or a functional equivalent thereof, for example a nucleic acid comprising from about nucleotide position 430 to about nucleotide position 1206 in Figure 19 or the entire nucleotide sequence shown in Figure 19. (SEQ ID No: 13)
- the human CED-6 amino acid sequence (SEQ ID NO: 16) is also shown in Figure 26. Amino acid sequence SEQ ID NO: 16 (human CED-6) and SEQ ID NO: 8 (hlCED-6) differ at amino acid No. 150.
- the nucleic acid sequence (SEQ ID NO: 15) that encodes human CED-6 is shown in Figure 30A-B.
- the claimed invention includes SEQ ID NOs: 15 and/or 16, the open reading frame of SEQ ID NO.: 15, and the nuclic acid and amino acid sequence that encoded the functional fragments, (e.g., serine/ protein rich region, the PTB domain or the highly charged domain), as described herein.
- the invention also provides a fusion protein in which one part of the fusion is a protein having an amino acid sequence as shown in any of SEQ ID Nos: 8, 14 or 16 or a sequence differing from acid sequences only in conservative amino acid changes.
- the protein may be fused with, for example, an epitope tag or expression product of a reporter gene.
- the present invention is intended to encompass CED-6 proteins (e.g., C. elegans CED-6, hi CED-6, h2 CED-6 and/or h3 CED-6) and polypeptides having amino acid sequences analogous to the amino acid sequences of CED-6.
- Such polypeptides are defined herein as CED-6 analogs (e.g., homologues), orthologs, or mutants or derivatives.
- Analogous amino acid sequences are defined herein to mean amino acid sequences with sufficient identity of CED-6 (e.g., C. elegans CED-6, hlCED-6, h2CED-6 or h3CED-6) amino acid sequence to possess the biological activity of CED-6.
- an analog polypeptide can be produced with "silent" changes in the amino acid sequence wherein one, or more, amino acid residues differ from the amino acid residues of the CED-6, yet still possesses the biological activity of CED-6. Examples of such differences include additions, deletions or substitutions of residues of the amino acid sequence of CED-6. Also encompassed by the present invention are analogous polypeptides that exhibit greater, or lesser, biological activity of the CED-6 proteins of the present invention.
- the claimed CED-6 protein and nucleic acid sequences include homologues, as defined herein. The homologous proteins and nucleic acid sequences can be determined using methods known to those of skill in the art.
- Initial homology searches can be performed at NCBI against the GenBank (release 87.0), EMBL (release 39.0), dbEST SwissProt (release 30.0) databases using the BLAST network service and other EST databases.
- Altshul, SF, et al Basic Local Alignment Search Tool. J. Mol. Biol. 215: 403 (1990), the teachings of which are incorporated herein by reference.
- Computer analysis of nucleotide sequences can be performed using the MOTIFS and the FindPatterns subroutines of the Genetics Computing Group (GCG, version 8.0) software. Protein and/or nucleotide comparisons can also be performed according to Higgins and Sharp (Higgins, D.G. and P.M.
- homologous proteins and/or nucleic acid sequences to the CED-6 protein and/or nucleic acid sequences that encode the CED-6 protein are defined as those molecules with greater than 70% sequences identity and/or similarity (e.g., 75%, 80%, 85%, 90%, or 95% homology).
- CED-6 proteins The "biological activity" of CED-6 proteins is defined herein to mean the ability to regulate or affect the phagocytosis of apoptotic cells.
- the claimed CED-6 proteins also encompasses biologically active polypeptide fragments of the CED-6 proteins, described herein.
- Such fragments can include only a part of the full-length amino acid sequence of an CED-6 yet possess the ability to modulate or regulate phagocytosis of apoptotic cells.
- polypeptide fragments comprising deletion mutants of the CED-6 proteins can be designed and expressed by well-known laboratory methods. Such polypeptide fragments can be evaluated for biological activity, as described herein.
- Antibodies can be raised to the CED-6 proteins and analogs, using techniques known to those of skill in the art.
- antibodies polyclonal, monoclonal, chimeric, or fragments thereof can be used to immunoaffinity purify or identify CED-6 proteins contained in a mixture of proteins, using techniques well known to those of skill in the art. These antibodies, or antibody fragments, can also be used to detect the presence of CED-6 proteins and homo logs in other tissues using standard immunochemistry methods.
- biologically active derivatives or analogs of the above described proteins including fragments and functional domains from c. elegans CED-6, hlCED-6, h2CED-6, or h3CED-6, referred to herein as peptide mimetics, can be designed and produced by techniques known to those of skill in the art. (see e.g., U.S. Patent Nos. 4,612,132; 5,643,873 and 5,654,276, the teachings of which are incorporated herein by reference). These mimetics can be based, for example, on a specific CED-6, hlCED-6 or h2CED-6 or h3CED-6 amino acid sequence and maintain the relative position in space of the corresponding amino acid sequence.
- peptide mimetics possess biological activity similar to the biological activity of the corresponding peptide compound, but possess a "biological advantage" over the corresponding CED-6 amino acid sequence with respect to one, or more, of the following properties: solubility, stability and susceptibility to hydrolysis and proteolysis.
- Methods for preparing peptide mimetics include modifying the N-terminal amino group, the C terminal carboxyl group, and/or changing one or more of the -35-
- a polypeptide can be in the form of a conjugate or a fusion protein, both of which can be made by known methods.
- Fusion proteins can be manufactured according to known methods of recombinant DNA technology.
- fusion proteins can be expressed from a nucleic acid molecule comprising sequences which code for a biologically active portion of the protein and its fusion partner, for example a portion of an immunoglobulin molecule.
- some embodiments can be produced by the intersection of a nucleic acid encoding immunoglobulin sequences into a suitable expression vector, phage vector, or other commercially available vectors.
- the resulting construct can be introduced into a suitable host cell for expression.
- the fusion proteins can be isolated or purified from a cell by means of affinity matrix.
- Expression vectors incorporating any of the above mentioned nucleic acids including those designated SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13 or 15, optionally with a reporter gene as aforesaid, are also provided by the invention.
- the present invention also encompasses isolated nucleic acid sequences encoding the CED-6 (e.g., C. elegans CED-6, hlCED-6, h2CED-6 or h3CED-6) proteins described herein, and fragments of nucleic acid sequences encoding biologically active CED-6 proteins. Fragments of the nucleic acid sequences, described herein, are useful as probes.
- nucleic acid sequences encompassed by the present invention are nucleic acid sequences, genomic DNA, cDNA, RNA or a combination thereof, which are substantially complementary to the DNA sequences encoding CED-6, and which specifically hybridize with the CED-6 DNA sequences under conditions of stringency known to those of skill in the art, those conditions being sufficient to identify DNA sequences with substantial nucleic acid identity.
- substantially complementary means that the sequence need not reflect the exact sequence of the CED-6 (e.g., C. elegans CED-6, hlCED-6, h2CED-6 or h3CED-6) DNA, but must be sufficiently similar in identity of sequence to hybridize with CED-6 DNA under stringent conditions. Conditions of stringency are described in e.g., Ausebel, F.M., et al, Current Protocols in
- non-complementary bases can be interspersed in the sequence, or the sequences can be longer or shorter than CED-6 DNA, provided that the sequence has a sufficient number of bases complementary to CED-6 to hybridize therewith. Exemplary hybridization conditions are described herein.
- h2CED-6 is consistent with it being a dominant negative version of hi or h3 CED-6 which antagonizes active of hi or h3CED-6.
- An assay for the identification of inhibitors and/or enhancers of phagocytosis may consist of a cell line stably or transiently transfected with CED-6, hlCED-6, h2CED-6, or h3CED-6 or any other member of the CED-6 signal transduction pathway.
- Cell lines may also be microinjected with purified protein or vectors expressing antisense RNA.
- the expression product may be a fusion protein with GFP.
- Non transfected cells can be used in the assay also.
- the cell line may be a fibroblast cell line such as COSI, BHK 21, L929, CV1, Swiss 3T3, HT144, IMR32 or another fibroblast cell line.
- the cell line may also be an epithelial cell line such as HEPG2, MDCK, MCF7, 293, Hela, A549, SW48, G361 , or any other epithelial cell line.
- the cell line may a primary line, such as human dermal FIBs, dermal keratinocytes, leucocytes, monocytes, macrophages, or any other primary cell line.
- Cells may be double transfected with other genes (like lectin, CD 14, SRA, CD36 ABC1, CED5, DOCK180) being from vertebrate (human fish, mouse) or invertebrate origin (C . elegans) .
- Phagocytosis assays consist of the addition of and uptake of particles and/or apoptotic cells, by these cell lines.
- the particle may be opsonized heat or chemically killed bacteria and yeast in a variety of sizes, shapes and natural antigenicities.
- the particle or cell may be an opsonized, fluorescently labeled, heat or chemically killed bacteria and yeast in a variety of sizes , shapes and natural antigenicities.
- the cell may be a apoptotic neutrophils, apoptotic lymphocytes, apoptotic erythrocytes or any other apototic cell. These apoptotic cells may be opsonized and/or labeled with dyes or fluorescent dyes.
- the killed bacteria or yeast cells and the apoptotic cells are referred to as herein apoptotic particles.
- Cells, transfected with CED-6 or any other gene described herein, for example, nucleic acids of SEQ ID Nos: 1, 3, 7, 9, 1 1, 13, or 15, can be grown in monolayer or in suspension.
- the apoptotic particles are added to the transfected cell. Phagocytosis can be followed by the uptake rate of the apoptotic particles. This can be measured by microscopy, by fluorescence microscopy, by quantitative spectrofiuorometry and by flow cytometry.
- Cells and or particles may additionally be labeled with dyes, fluorescent dyes, antibodies and dyes of fluorescent dyes linked to antibodies prior to detection and measurement. Decrease or increase of the uptake of the apoptotic particles is a measurement for the influence of the transfected gene or genes in the phagocytosis.
- Compounds can be added to assay 1 to test their influence on the genes that are involved in the phagocytosis pathway. Transiently or stably transfected cells are grown in suspension or in monolayer. A series of compounds is added to the cells prior to the addition of the apoptotic particles. The influence of the compounds can be measured by comparing the uptake rate of the apoptotic particles with and without the addition of the compound. Measurements are described in Assay 1
- Mammalian cells are able to phagocytose apoptotic particles by engulfment of particles. This involves the reorganization of the actin cytoskeleton.
- Mammalian cells may be transiently or stably transfected with CED-6 or any gene involved in the CED-6 -39-
- phagocytosis signal transduction pathway for example, with a nucleic acid have the sequence of nucleotides shown in any one of SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13 or 15.
- Cells can be any cell as described in Assay I .
- the genes may be expressed as a GPF fusion product.
- Cells may be double transfected (see Assay 1).
- the reorganization of the actin cytoskeleton can be visualized with fluorescent dyes linked to phalloidine, which interacts with F-actin.
- Reorganization of the cytoskeleton is an measurement for the engulfment induction by the transfected gene or genes.
- Transfected cells may be treated with particles or apoptotic cells as described in Assay 1. Reorganization of the cytoskeleton is visualized by microscopy or fluorescence microscopy.
- Compounds can be added to Assay 3 to test their influence on the genes that are involved in the cytoskeleton reorganization related to the phagocytosis pathway and engulfment. These compounds may enhance or inhibit the engulfment or cytoskeleton reorganization induced by the introduced genes.
- Transiently or stably transfected cells are grown in suspension or in monolayer. A series of compounds is added to the cells. The influence of the compounds can be measured by comparing the reorganization of actin cytoskeleton with and without the addition of the compound. Measurements as are described in Assay 1, Assay 2 and Assay 3. Apoptotic particles may be added in this test to induce phagocytosis, as described in Assay 2.
- Non-transfected or transfected cell-lines such as those described above may be microinjected with purified CED-6 protein, for example, a protein having the amino acid sequence as shown in SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14, or 16 or any protein from the CED-6 pathway or a fusion protein comprising any of said proteins.
- Microinjection can be done on the primary cell lines or the fibroblast cell lines or the other epithelial cells lines.
- the cell lines can be transfected with another gene prior to micro injections.
- Assays 1 through Assay 4 can be performed on these microinjected cells. -40-
- Transfected or non-transfected cell-lines as described above may be microinjected with a vector expressing CED-6 antisense RNA including antisense RNA in respect of any of the aforementioned proteins or any antisense RNA for genes involved in the CED-6 pathway.
- Micro injection can be done on the primary cell lines or the fibroblast cell lines or the epithelial cell lines.
- the cell lines can be transfected with another gene prior to microinjection.
- Assays 1 through Assay 5 can be performed on these microinjected cells.
- Assay 7 Cell lines, as described in Assay 6 may be micro-injected with a vector expressing CED-6 antisense RNA or any antisense RNA for genes involved in the CED-6 pathway. Microinjection can be done on the macrophages. Inhibitory effects of the antisense RNA by inhibition of the CED-6 gene or genes involved in the CED-6 pathway can be followed and detected as described in Assay 1 through Assay 6. Compounds can be isolated which rescue the negative phenotype.
- the C. elegans CED-6 gene promotes the engulfment of dying embryonic and germ cells and persistent cell corpses.
- C. elegans may be used for detection and isolation of compounds that have an enhancing or inhibitory influence on phagocytosis and engulfment.
- mutant worms lacking CED-6 activity or with otherwise altered CED-6 activity may be used or alternatively a transgenic worm transfected or transferred with CED-6, hlCED-6, h2CED-6, or h3CED-6 DNA may be used.
- Assay 8 A series of compounds may be applied on CED-6 mutant worms or on worms harboring mutations in the CED-6 pathway. Restoration of engulfment induced by the compounds can be visualized using Nomarski microscopy by 770
- a series of compounds may be applied on humanized CED-6 mutant worms.
- Humanized worms are worms expressing the human CED-6 gene and are mutated for the C. elegans gene. Human CED-6 rescues the mutant phenotype.
- Compounds inhibiting or enhancing the CED-6 phenotype can be selected by visualization of the engulfment phenotype using Nomarski microscopy and looking for cell corpses as aforesaid.
- apoptosis has been implicated in the etiology - or associated with the pathology - of a wide range of diseases, including cancer, autoimmune diseases, various neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Huntington's Disease, and Alzheimer's Disease, stroke, myocardial heart infarct, and AIDS (Thompson, 1995).
- diseases including cancer, autoimmune diseases, various neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Huntington's Disease, and Alzheimer's Disease, stroke, myocardial heart infarct, and AIDS (Thompson, 1995).
- a better understanding of the molecular events that underlie apoptosis might lead to novel therapeutic interventions. While much of the current attention is centered on the genes and proteins that control the killing step of the death process, it is very likely that the removal of apoptotic cells will prove to also be crucial for the proper overall functioning of the apoptotic program, and will offer another entry point for therapeutic intervention.
- activation of engulfment could be used for the same cases for which it is proposed to use activation of apoptosis, e.g., cancer. Indeed, specific activation within the cancer cells of the pro-engulfing signal would lead to the cells' removal - (and death) - without needing to activate the rest of the apoptotic machinery. This could be particularly useful for highly resistant tumors in which crucial elements of the central apoptotic machinery have already been inactivated.
- the invention provides a method of treating, for example inflammation, autoimmune disease and cancer by administering to a patient an effective amount of a substance which enhances phagocytosis of apoptoic cells, in particular a substance which enhances the activity of hl-CED6, h3-CED-6 or the signal transduction pathway in which it participates.
- Such substances includes hl-CED 6 or h3-CED-6 itself, a nucleic acid encoding hl- CED6 or h3-CED-6, an anti-sense nucleic acid to hi , h2 or h3 CED-6 or compounds identified in any of the aforementioned assays as enhancers of CED-6, hl-CED-6, h2-CED-6, or h3-CED-6 or of transcription thereof.
- the invention also enables a method of treatment of, for example, neurodegenerative diseases, stroke and sickle-cell anaemia by administering to a patient an effective amount of a substance which inhibits phagocytosis of apoptotic cells, in particular a substance which inhibits the activity of hl-CED6 or h3-CED6 -43-
- Such substances include h2 CED-6, a nucleic acid encoding h2CED-6, an anti-sense nucleic acid to hlCED-6 or h3CED-6 or compounds identified in any of the aforementioned assays as inhibitors of CED-6 or hlCED-6 or h3CED-6 or of transcription thereof.
- Pharmaceutical compositions comprising any of the above-mentioned therapeutic substances and a pharmaceutically acceptable carrier are also envisaged by the invention.
- a nucleic acid which encodes hi, h2 or h3 CED-6 or a functional portion or domain thereof must be introduced into a mammalian cell (e.g., mammalian somatic cell, mammalian germ line cell (sperm and egg cells)).
- a mammalian cell e.g., mammalian somatic cell, mammalian germ line cell (sperm and egg cells)
- a nucleic acid vector e.g., a DNA vector such as a plasmid, virus or other suitable replicon (e.g., a viral vector), which can be present in a single copy or multiple copies.
- the nucleic acid may be transfected or transformed into cells using suitable methods known in the art such as electroporation, microinjection, infection, and lipoinfection and direct uptake. Such methods are described in more detail, for example, in Sambrook et al, "Molecular Cloning: A Laboratory Manual," 2nd ED. (1989), Ausubel, F.M., et al, Current Protocols in Molecular Biology, (Current Protocol, 1994) and Sambrook et al, "Molecular Cloning: A Laboratory Manual," 2nd ED. (1989).
- hi, h2 or h3 CED-6 can be delivered to a cell by the use of viral vectors comprising one or more nucleic acid sequences encoding those proteins.
- the nucleic acid sequence has been incorporated into the genome of the viral vector.
- the viral vector containing hi, h2 or h3 CED-6 protein described herein or nucleic acid sequences encoding the protein can be contacted with a cell and infectivity can occur.
- the cell can then be used experimentally to study phagocytosis of apoptotic cells or for assays as aforesaid or be implanted into a patient for therapeutic use.
- the cell can be migratory, such as hematopoietic cells, or non-migratory such as a solid tumor or fibroblast.
- the cell can be present in a -44-
- biological sample obtained from the patient e.g., blood, bone marrow
- used in the treatment of disease or can be obtained from cell culture.
- the sample can be returned or readministered to a cell culture or patient according to methods known to those practiced in the art.
- a treatment procedure is sometimes referred to as ex vivo treatment or therapy.
- the cell is targeted from the patient or animal and returned to the patient or animal once contacted with the viral vector comprising the activated mutant of the present invention.
- Ex vivo gene therapy has been described, for example, in Kasid, et al, Proc. Natl. Acad. Sci.
- the cell incorporating the viral vector comprising a nucleic acid sequence of hi CED-6, h2 CED-6 or h3CED-6 can be implanted into a patient or experimental animal model for delivery or used in In vitro experimentation to study cellular events mediated by hi, h2 or h3 CED-6.
- Various viral vectors can be used to introduce the nucleic acid into mammalian cell. Viral vectors include retrovirus.
- adenovirus parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses such as picomavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalo virus), and poxvirus (e.g., vaccinia, fowlpox and canarypox).
- orthomyxovirus e.g., influenza virus
- rhabdovirus e.g., rabies and vesicular stomatitis virus
- paramyxovirus e.g. measles and Send
- viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
- retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D- type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J.M., Retroviridae: -45-
- viruses and their replication In Fundamental Virology, Third Edition, B.N.
- murine leukemia viruses include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus,
- Gibbon ape leukemia virus Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus, lentiviruses and baculoviruses.
- engineered viral vectors provide a means to introduce nucleic acids into cycling and quiescent cells, and have been modified to reduce cytotoxicity and to improve genetic stability.
- engineered Herpes simplex virus type 1 D.M. Krisky, et al., Gene
- the claimed invention encompasses various therapeutic uses as aforesaid for the hi, h2 or h3 CED-6 protein or nucleic acid.
- the protein may be administered using methods known in the art.
- the mode of administration is preferably at the location of the target cells.
- the administration can be nasally (as in administering a vector expressing
- ADA a vector expressing a suicide gene tumor
- agents can, preferably, be administered in a pharmaceutically acceptable carrier, such as saline, sterile water,
- the invention also provides diagnostic reagents which may be used in the diagnosis of a disease associated with a defect in phagocytosis of apoptotic cells.
- diagnostic reagents which may be used in the diagnosis of a disease associated with a defect in phagocytosis of apoptotic cells.
- an antibody to an epitope of any of the proteins with an amino acid sequence as shown in SEQ ID Nos: 2, 4, 6, 8, 10, 12, 14 or 16 could be used as a -46-
- diagnostic reagent to determine whether a patient has a defect in hlCED-6, h2CED- 6 or h3CED-6 or in the expression thereof.
- defects at the genetic level can be detected by using as a probe a nucleic acid having a sequence as shown in SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, or 15 or portions thereof.
- Identification of the other proteins active in the CED-6 signal transduction pathway CED-6, hlCED-6, h2CED-6 or h3CED-6 can be used to identify other members of the signal transduction pathway promoting phagocytosis of apoptotic cells.
- a preferred method is the so-called "two hybrid" system developed in yeast by Chien et al (1994, Proc. Natl. Acad Sci. USA 88 pp 9578-9582) which allows identification of proteins which bind to a particular protein of interest.
- This technique is based on functional in vivo reconstruction of a transcription factor which activates a reporter gene. More particularly the technique comprises providing an appropriate host cell, preferably yeast, with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA binding domain and an activating domain, expressing in the host cell a first hybrid DNA sequence encoding a first fusion of a fragment or all of a nucleic acid sequence according to the invention and either said DNA binding domain or the activating domain of the transcription factor, expressing in the host cell at least one second hybrid DNA sequence encoding putative binding proteins to be investigated together with the DNA binding domain or activating domain of the transcription factor which is not incorporated in the first fusion; detecting any binding of the protein being investigated with a protein according to the invention by detecting for the production of any reporter gene product in the host cell; optionally isolating second hybrid DNA sequence encoding the binding protein.
- N2 Bristol strain was used as the reference wild-type strain for this study. All strains were maintained as described by Brenner (Brenner, 1974), except -47-
- LG I ced-l(el735), ced-l(nl995) and ced-l(nl506) (Ellis et al, 1991); LG III: dpy-17(el64), ced-6(nl813, n2095), mec-14(u55), ncl-l(el865) ced-7(nl997), ced- 7(nl892), cedX(n!996) (Ellis et al, 1991 ), unc-36(e251) (Brenner, 1974) and sDp3(III, ) (Rosenbluth et al, 1985); on LG IV: ced-2(e!752) (Hedgecock et al, 1983), ced-5(nl812) and ced-10(nl993) (Ellis e
- Transgenic animals were generated using the germline microinjection procedure developed by Mello et al. Cosmids W03A5, F20F10, F48E8, R02F2, W02G12, T06H6, C48E6, C44D7, F56D2, F43F12, C05D2, T06C9, C05H8 were injected, either singly or in groups (final concentration 20ng/ul for each cosmid), into ced-6(nl813) animals.
- Plasmid pRF4 was used (final concentration 50-80 ng/ul) as the dominant co-injection marker (Mello et al., 1991); pRF4 carries the mutated collagen gene rol-6(su!006gf) and confers a dominant roller (Rol) -48-
- Transgenic lines carrying stably transmitting extrachromosomal arrays were kept for further analysis.
- To assay for rescue three-fold embryos laid by transgenic animals were examined for cell corpses under Normaski optics. Transgenic lines that generated embryos with fewer or no corpses were considered to be rescued.
- Reverse transcription (RT)-PCR experiments were performed to determine the 5'end of transcripts detected or predicted within the rescuing Xho I genomic fragment. Reverse transcription was performed with following primers: C05D2.6a: GAATCTGTCCATCGCATTGC (SEQ ID NO.: 18), GAATTTCTTTGGGTAGACA (SEQ ID NO.: 19); C05D2.6b:
- GCTCTGAAGAACTGTGA SEQ ID NO.: 20
- GACGAGGTGAAGCGATTGTG SEQ ID NO.: 21
- SL1 GTTTAATTACCCAAGTTTGAG (SEQ ID NO.: 23)
- SL2 GGTTTTAACCCAGTTACTCAAG (SEQ ID NO. : 24)
- ced-6 allele resulted in a large physically detectable polymorphism
- Southern blots of N2, ced-6(nl813), and ced-6(n2095) genomic DNA digested with various restriction enzymes A probe generated from the rescuing Xho I genomic fragment detected noval allele-specific bands in ced-6(n2095) using four different restriction enzymes. Analysis of the novel restriction patterns in ced-6(n2095) indicates that this allele carries a complex rearrangement in this region, that covers at least part of F56D2.7, but does not affect the neighboring C05D2.6b transcript.
- Kpn VSal I fragment of full-length F56D2.7 cDNA was inserted in Kpn VSac I site of MCS II of both pPD49.78 and pPD49.83 vectors which carry hspl6-2 and hspl6-41 promoters, creating the constructs pLQhsl and pLQhs2. The two constructs were co-injected, at
- L4 stage transgenic animals were transferred to new plates and stored at 20°C. Starting 24 hours after the L4 molt, the worm plates were parafilmed and heat shocked for 45 minutes at 33°C as described above.
- L4 stage transgenic animals were collected and put into several plates, a few for each plate.
- each plate of worms at one time point were treated with heat. Animals were examined for germ cell corpses 12 hours after heat shock.
- ced-6 or lacZ-expressing extrachromosomal arrays were transferred from ced-6(nl813) to a wild-type background, and crossed subsequently to ced- 1 (el 735) ced-l(nl506), ced-l(nl995), ced-7(1892), ced-7(nl996), ced-7(nl997), ced-2(nl752), ced-5(nl812) or ced-10(nl993) to generate the corresponding transgenic mutant strains.
- Heat shock experiments were performed as described above.
- RNA Blots see Figure 25 expression pattem of hCED-6 in normal human tissues and cancer cell lines by Northern blotting
- RNA blot from human cancer cell lines (melanoma G361, lung carcinoma A549, colorectal adenocarcinoma SW480, Burkitt's lymphoma Raji Leukemia Molt 4, lympohoblastic leukemia K562, HeLa S3 and promyelocytic leukemia HL60) was tested. -53-
- ⁇ gtlO cDNA libraries purchased from Clontech
- the primer Q and a primer against ⁇ gtlO vector were used to isolate several PCR fragments using brain and pancreas cDNA libraries. These PCR fragments were reamplified using the same primer set and sequenced. The sequence analysis suggested that these PCR fragments allows the extension of cDNA 130bp upstream of the initiation codon of human ced-6 coding region. The longest PCR fragment was then sent to human EST database to search for more EST clones which have overlap with the isolated PCR fragments but not the hbc3123 EST clone. The Genbank names of these three EST clones are R65982, R65983 and AA159394, respectively.
- hced-6 which encompasses hi CED-6 and/or h3CED-6
- hced-6 which encompasses hi CED-6 and/or h3CED-6
- DOCK180 the mammalian homologue ofC. elegans CED-5, efficiently rescued the distal tip cell migration defect of CED-5 mutants, but not the engulfment defect.
- the open reading frame of hced-6 was PCR- amplified using oligonucleotides flanking the start and stop codons, and subcloned into the heat shock vectors pPD49.78 and pPD49.83, previously digested with Kpn I and Sac I (see before). The two constructs were then injected into ced-6(n!813) animals as described previously to establish stably transmitting transgenic lines.
- transgenic animals were submitted to heat-shock and the number of cell corpses quantified as described previously herein. -57-
- Hhsl GGGGTACCGAATTCTGATGGCAAC; (SEQ ID NO.:27)
- Hhs3 CGAGCTCGATCAATAGTGAAGGTGAGG; (SEQ ID NO.: 28)
- the PCR fragment was digested subsequently with Kpn I and Sac I, and inserted into Kpn I and Sac I sites of both ppD49.78 and ppD49.83 heat shock vectors.
- nced-6 was examined for its ability to rescue the engulfment defect in embryo progeny of ced-6(nl 813) transgenic animals following an established procedure, as described herein.
- Sequences can be obtained in both deposits using T3 or T7 primers (either one or both can be used, they are at different sites of the actual insert). Both are commercially available from Clontech (#1227 and #1228) and sequence is shown below
- T7 primer 5'(TAATACGACTCACTATAGGGAGA)3' (SEQ ID NO.: 25)
- T3 primer 5'(ATTAACCCTCACTAAAGGGA)3' (SEQ ID NO.: 26)
- a cell that dies during wild-type C. elegans development can function as a neuron in a ced-3 mutant.
- the mec-4 gene is a member of a family of Caenorhabditis elegans genes that can mutate to induce neuronal degeneration. Nature 349, 588-593.
- the PTB domain a new protein module implicated in signal transduction.
- Gout I., Dhand, R., Hiles, I. D., Truong, O., Totty, N. F., Hsuan, J., Booker, G. W., Campbell, L. D., and Waterfield, M. D. (1993).
- the GTPase dynamin binds to and is activated by a subset of SH3 domains. Cell 75, 25-36.
- C. elegans cell survival gene ced-9 encodes a functional homologue of the mammalian proto-oncogene bcl-2. Cell 76, 665-676.
- SH2 and SH3 Domains elements that control interactions of cytoplasmic signaling proteins. Science 252, 252-673.
- the Caenorhabditis elegans rol-6 gene which interacts with the sqt-1 collagen gene to determine organismal morphology, encodes a collagen. Molecular and cellular Biology 10, 2081-2089. -63-
- Anti-apogens and anti-engulfens monoclonal antibodies reveal specific antigens on apoptotic and engulfment cells during chicken embryonic development. Development 120, 1421-1431.
- Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90, 1513-1522.
- Operons in C. elegans polycistronic mRNA precursors are processed by trans-splicing of SL2 to downstream coding region. Cell 73, 521-532.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000528677A JP2003525569A (en) | 1998-01-23 | 1999-01-21 | Phagocytic genes and uses thereof |
AU22408/99A AU746409B2 (en) | 1998-01-23 | 1999-01-21 | Phagocytosis genes and uses thereof |
CA002318935A CA2318935A1 (en) | 1998-01-23 | 1999-01-21 | Phagocytosis genes and uses thereof |
EP99902425A EP1049776A1 (en) | 1998-01-23 | 1999-01-21 | Phagocytosis genes and uses thereof |
HU0101593A HUP0101593A2 (en) | 1998-01-23 | 1999-01-21 | Phagocytosis genes and uses thereof |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7232498P | 1998-01-23 | 1998-01-23 | |
US60/082,324 | 1998-01-23 | ||
US9634798A | 1998-06-11 | 1998-06-11 | |
US81266098A | 1998-06-11 | 1998-06-11 | |
US09/096,731 | 1998-06-11 | ||
US09/096,347 | 1998-06-11 | ||
US09/096,731 US6489454B1 (en) | 1998-01-23 | 1998-06-11 | Engulfment gene and uses thereof |
GBGB9812660.0A GB9812660D0 (en) | 1998-06-11 | 1998-06-11 | Engulfment gene and uses thereof |
GB9812660.0 | 1998-06-11 | ||
US82081698A | 1998-09-24 | 1998-09-24 | |
GBGB9820816.8A GB9820816D0 (en) | 1998-09-24 | 1998-09-24 | Engulfment gene and uses thereof |
GB9820816.8 | 1998-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999037770A1 true WO1999037770A1 (en) | 1999-07-29 |
Family
ID=56289881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/001361 WO1999037770A1 (en) | 1998-01-23 | 1999-01-21 | Phagocytosis genes and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1999037770A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2356400A (en) * | 1999-11-18 | 2001-05-23 | Devgen Nv | Drosophila CED-6 homologue and its uses |
WO2001088114A2 (en) * | 2000-05-19 | 2001-11-22 | Devgen Nv | Gene expression system |
US6723557B1 (en) | 1999-01-06 | 2004-04-20 | California Institute Of Technology | Caenorhabditis elegans LOV-1 gene |
US7083947B2 (en) | 2000-05-19 | 2006-08-01 | Devgen Nv | Assay techniques using nematode worms |
US20180360755A1 (en) * | 2015-06-15 | 2018-12-20 | University Of Virginia Patent Foundation | Target-specific delivery of therapeutic agents |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020237A1 (en) * | 1992-04-01 | 1993-10-14 | Cambridge Neuroscience, Inc. | Homology cloning |
-
1999
- 1999-01-21 WO PCT/US1999/001361 patent/WO1999037770A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020237A1 (en) * | 1992-04-01 | 1993-10-14 | Cambridge Neuroscience, Inc. | Homology cloning |
Non-Patent Citations (9)
Title |
---|
BORK, P. AND MARGOLIS, B.: "a phosphotyrosine interaction domain", CELL, vol. 80, 1995, pages 693 - 694, XP002105770 * |
DRISCOLL, M.: "cell death in C. elegans: molecular insights into mechanisms conserved between nematodes and mammals", BRAIN PATHOLOGY, vol. 6, 1996, pages 411 - 425, XP002105768 * |
ELLIS, R.E., ET AL.: "genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans", GENETICS, vol. 129, September 1991 (1991-09-01), pages 79 - 94, XP002105767 * |
HILLIER, L., ET AL.: "WashU-Merck EST project 1997", EMBL SEQUENCE DATA LIBRARY, 25 May 1997 (1997-05-25), heidelberg, germany, XP002105766 * |
KOHARA, Y., ET AL.: "expression map of the C. elegans genome", EMBL SEQUENCE DATA LIBRARY, 8 September 1997 (1997-09-08), heidelberg, germany, XP002105765 * |
LIU, Q.A., ET AL.: "candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C. elegans", CELL, vol. 93, June 1998 (1998-06-01), pages 961 - 972, XP002105771 * |
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES VI. THE CODING SEQUENCES OF 80 NEW GENES (KIAA0201-KIAA0280) DEDUCED BY ANALYSIS OF CDNA CLONES FROM CELL LINE KG-1 AND BRAIN", DNA RESEARCH, vol. 3, no. 5, 1 January 1996 (1996-01-01), pages 321 - 329, XP002068376 * |
RAMESH, N., ET AL.: "WIP, a protein associated with Wiskott-Aldrich syndrome protein, induces actin polymerisation and redistribution in lymphoid cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 94, 1997, pages 14671 - 14676, XP002105769 * |
WILSON R ET AL: "2.2 MB OF CONTIGUOUS NUCLEOTIDE SEQUENCE FROM CHROMOSOME III OF C ELEGANS", NATURE, vol. 368, 3 March 1994 (1994-03-03), pages 32 - 38, XP002050139 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6723557B1 (en) | 1999-01-06 | 2004-04-20 | California Institute Of Technology | Caenorhabditis elegans LOV-1 gene |
US6849717B1 (en) | 1999-01-06 | 2005-02-01 | California Institute Of Technology | Polycystic kidney disease gene homologs required for male mating behavior in nematodes and assays based thereon |
GB2356400A (en) * | 1999-11-18 | 2001-05-23 | Devgen Nv | Drosophila CED-6 homologue and its uses |
WO2001036458A2 (en) * | 1999-11-18 | 2001-05-25 | Devgen Nv | Drosophila ced-6 homologue |
WO2001036458A3 (en) * | 1999-11-18 | 2002-01-10 | Devgen Nv | Drosophila ced-6 homologue |
WO2001088114A2 (en) * | 2000-05-19 | 2001-11-22 | Devgen Nv | Gene expression system |
WO2001088114A3 (en) * | 2000-05-19 | 2002-06-20 | Devgen Nv | Gene expression system |
US7083947B2 (en) | 2000-05-19 | 2006-08-01 | Devgen Nv | Assay techniques using nematode worms |
US20180360755A1 (en) * | 2015-06-15 | 2018-12-20 | University Of Virginia Patent Foundation | Target-specific delivery of therapeutic agents |
US11369569B2 (en) * | 2015-06-15 | 2022-06-28 | University Of Virginia Patent Foundation | Target-specific delivery of therapeutic agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7846681B2 (en) | Apoptosis modulator BCL-B and methods for making and using same | |
Prakash et al. | Functional analysis of ARHGAP6, a novel GTPase-activating protein for RhoA | |
US6838444B1 (en) | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation | |
JPH10513359A (en) | Inhibitors of cyclin-dependent kinases CDK4 and CDK6, InK4c-p18 and InK4d-p19, and uses thereof | |
US6900367B2 (en) | Transgenic Drosophila melanogaster expressing a β42 in the eye | |
JP4005135B2 (en) | Use of neuronal apoptosis inhibitory protein (NAIP) | |
US6307019B1 (en) | Axin gene and uses thereof | |
US7053200B1 (en) | Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation | |
WO1999037770A1 (en) | Phagocytosis genes and uses thereof | |
AU746409B2 (en) | Phagocytosis genes and uses thereof | |
US6489454B1 (en) | Engulfment gene and uses thereof | |
Shandala et al. | The Drosophila retained/dead ringer gene and ARID gene family function during development | |
AU749896B2 (en) | Methods and reagents for modulating apoptosis | |
WO2003047532A2 (en) | Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition | |
MXPA00007149A (en) | Phagocytosis genes and uses thereof | |
AU8511098A (en) | Sel-10 and uses thereof | |
CA2823479C (en) | Compositions for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation | |
US20020064523A1 (en) | Synthetic multivulva (synmuv) polypeptides | |
Boylan | A molecular genetic analysis of cytoplasmic dynein function in Drosophila melanogaster | |
WO1998011209A1 (en) | Skap55 compositions and methods of use therefor | |
Chartrand | Functional analysis of Dlx homeodomain proteins from the zebrafish. | |
Zhu | SPE-39 is required for intracellular membrane reorganization during spermatogenesis and many other aspects of Caenorhabditis elegans development | |
Crowley | The candidate tumor suppressor genes gelsolin and p140mRhoGAP in mouse mammary gland development and neoplasia | |
JPH1132780A (en) | Xaf gene and polypeptide: regulation of apoptosis and reagent therefor | |
CA2252422A1 (en) | Methods and reagents for modulating apoptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US US US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 22408/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2318935 Kind code of ref document: A Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/007149 Country of ref document: MX Ref document number: 09621790 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 528677 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999902425 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999902425 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 22408/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999902425 Country of ref document: EP |